中国当代医药2025，Vol.32Issue(23)：35-38,4.DOI:10.3969/j.issn.1674-4721.2025.23.07
替莫唑胺联合来那度胺治疗老年复发脑胶质瘤的临床观察
Clinical observation of Temozolomide combined with Lenalidomide in the treatment of recurrent glioma in the elderly patients
摘要
Abstract
Objective To explore the therapeutic effect of Temozolomide combined with Lenalidomide in the treatment of elderly patients with recurrent glioma.Methods A total of 90 elderly patients with recurrent glioma admitted to Hongqi Hospital Affiliated to Mudanjiang Medical University from February 2023 to February 2024 were selected as the research subjects and they were divided into the control group(45 cases)and the experimental group(45 cases)according to the random number table method.The control group was treated with Temozolomide,while the experimental group was treated with Temozolomide combined with Lenalidomide.The adverse reactions,therapeutic effects and quality of life of the two groups of patients were compared.Results The total effective rate of the experimental group was higher than that of the con-trol group,and the difference was statistically significant(P＜0.05).The total incidence of adverse reaction of the experi-mental group was lower than that of the control group,and the difference was statistically significant(P＜0.05).After treat-ment,the quality of life score of the experimental group was higher than that of the control group,and the difference was statistically significant(P＜0.05).Conclusion The application of Temozolomide combined with Lenalidomide in the treat-ment of elderly recurrent glioma can reduce the incidence of adverse reactions,improve the overall therapeutic effect,and help enhance the quality of life of patients after prognosis.It is worthy of further promotion and application in clinical practice.关键词
替莫唑胺/来那度胺/老年复发脑胶质瘤/疗效观察Key words
Temozolomide/Lenalidomide/Recurrent gliomas in the elderly patient/Observation of curative effect分类
医药卫生引用本文复制引用
程显枝,梁晶,宋铁军..替莫唑胺联合来那度胺治疗老年复发脑胶质瘤的临床观察[J].中国当代医药,2025,32(23):35-38,4.基金项目
黑龙江省省属高等学校基本科研业务费科研项目(2024-KYYWF-0514). （2024-KYYWF-0514）
